mCuMVTT-RBM induces higher antibody titers in
comparison to SARS-CoV-2 convalescent sera
In comparison to infections with other viruses, patients infected with
COVID-19 produce neutralizing antibodies at relatively low levels (27,
32). Hence, we compared the total RBD-specific IgG titer induced in
mouse sera after vaccination with mCuMVTT-RBM to
SARS-CoV-2 convalescent sera (total of 5 different sera). The results
showed that the vaccine induces higher RBD-specific antibody titers even
after a single priming dose compared to natural infection with
SARS-CoV-2 and the booster injection further increased the RBD-specific
antibody responses (Fig. 5A and B). Analysis of Area Under Curve (AUC)
indicated a high difference (p <0.0001) between mouse
sera collected on day 14 (after priming) or day 42 (after boost) to
convalescent sera (Fig. 5C and D).